inhibitors, describe their mechanism of action, and their potential for future development.
the cell membrane and from there are incorporated into budding EBOV particles. GP 1 contains 48 the receptor-binding site [15, 16] , whereas GP 2 contains a hydrophobic fusion peptide at the N-49 terminus followed by N-and C-terminal heptad repeats (NHR and CHR, respectively) and a 50 transmembrane domain that anchors the GP 1,2 trimer to the membrane [16] [17] [18] [19] .
51
Ebola virion host-cell entry 52 The initiation of EBOV host-cell entry is incompletely understood. It is currently hypothesized 
81
Ebola virus cell-entry inhibitors 82 Candidate MCMs, which include antibodies, small molecules, and peptides, can target various 83 stages of the described EBOV cell-entry pathway. The majority of promising MCMs interrupt 84 virion attachment to cell-surface attachment factors, the intracellular EBOV receptor NPC1, 85 proteolytic processing of GP 1,2 , or fusion of the viral envelope with the endosomal membrane.
86
These therapeutic agents can be designed to act directly against the Ebola virion (e.g., antibody 87 cocktails targeting the virion surface GP 1,2 ) or to act indirectly by targeting the host cell (e.g.,
88
prevent acidification of endosomes, inhibit cathepsins, block NPC1 receptor While antibody monotherapy may provide a simplified therapeutic strategy to treat EVD, 165 an antibody cocktail therapy may be more potent and less brittle to viral neutralization escape. 
251
Interrupting the cellular endocytotic pathway is a promising avenue to counter EBOV 252 infection because EBOV is critically dependent on endocytosis to gain entry into host cells. TR-17-011 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
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In vitro and in vivo studies evaluating potential additive or even synergistic effects of 321 multiple compounds with different mechanisms of action have not been published thus far.
322
However, most EVD patients with access to modern healthcare will be treated following multiple TR-17-011 DISTRIBUTION STATEMENT A: Approved for public release; distribution is unlimited.
UNCLASSIFIED
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EXECUTIVE SUMMARY
343
EBOV particle attachment to cells and internalization
344
• EBOV glycoprotein (GP 1,2 ) trimers on virions attach to host-cells via attachment factors.
345
• Virions internalizes into endosomes through a macropinocytosis-like process.
346
• Acidic environment in endosomes triggers cysteine proteases to remove the glycan cap of the 347 GP 1 subunit.
348
• Trimmed GP 1,2 trimers bind to endosomal NPC1.
349
• GP 2 -mediated fusion to endosome occurs after NPC1 binding.
350
Entry inhibitors as antiviral agents
351
• Sertraline and bepridil inhibit EBOV particle cell entry and protect laboratory mice from 352 lethal disease.
353
Monoclonal antibodies
354
• Certain antibodies block surface-exposed GP 1,2 epitopes or the internal GP 1 -NPC1 receptor-355 binding site.
356
• ZMapp, a monoclonal antibody cocktail, plus supportive care were beneficial in clinical 357 phase I-II trials, but ZMapp alone was not superior over supportive care alone. 
